Published • loading... • Updated
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) said it recently published data supporting the use of skin-based frataxin measurements as a surrogate endpoint for its experimental therapy nomlabofusp, a step that could enable an accelerated U.S. approval pathway for Friedreich’s ataxia. The company said the findings, published in Clinical and Translational Science (https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70565), show th…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
